BRAF and metastatic melanoma: Combination therapies can also involve three drugs, such as in the case of vemurafenib, cobimetinib, and the PD-L1 blocking antibody atezolizumab; this trio was FDA-approved for treating unresectable or metastatic melanomas with any BRAF V600 mutation [19].